Celltrion Healthcare IPO Set To Benefit From Biosimilar Successes
Executive Summary
Amid Celltrion's string of biosimilar approvals and launches in the US and Europe, its marketing and distribution arm Celltrion Healthcare seems to have picked the perfect timing to launch an IPO.
You may also be interested in...
Celltrion Healthcare IPO To Accelerate Celltrion's Global Biosimilar Expansion
Celltrion Healthcare's initial public offering, which is seen as the most anticipated biotech IPO in South Korea's Kosdaq market this year, is set to speed up Celltrion's expansion of its global market presence as well as the development of biosimilars and novel drugs.
Celltrion Healthcare IPO To Accelerate Celltrion's Global Biosimilar Expansion
Celltrion Healthcare's initial public offering, which is seen as the most anticipated biotech IPO in South Korea's Kosdaq market this year, is set to speed up Celltrion's expansion of its global market presence as well as the development of biosimilars and novel drugs.
Celltrion's Truxima First Biosimilar MAB In Oncology To Win EU Approval
Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.